secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001437749-25-018698
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma gets FDA approval for KHINDIVI oral solution; peak sales >$50M
--------------------------------------------------------------------------

- KHINDIVI is the first and only FDA-approved hydrocortisone oral solution for pediatric adrenocortical insufficiency.
- Commercial launch expected week of June 2, 2025; product distributed through Anovo specialty pharmacy.
- Combined peak sales of KHINDIVI and ALKINDI SPRINKLE expected to exceed $50 million per year.
- Indicated for patients 5 years and older; eliminates need to split or crush tablets for accurate dosing.
- Eton's rare disease sales team to promote alongside ALKINDI SPRINKLE; Eton Cares program offers $0 co-pay for qualifying patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925018698/0001437749-25-018698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925018698/eton20250522_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-018698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer